Skip to main content
Top

2006 | OriginalPaper | Hoofdstuk

Hoe is het beleid rondom staken en weer starten van antistollingsbehandeling?

Auteur : Prof.dr. C. Haanen

Gepubliceerd in: Vademecum permanente nascholing huisartsen

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Het beleid met betrekking tot het staken en hervatten van een antistollingsbehandeling hangt grotendeels af van de indicatie waarvoor de antistolling wordt gegeven, van het antistollingsmiddel dat wordt gebruikt en van de omvang en de plaats van de voorgenomen ingreep. In geval van een profylactische of kortdurende antistollingsbehandeling (< 3 maanden) is de indicatie niet zo zwaarwegend dat wachten met de ingreep of staken van de therapie verantwoord is. Uiteraard dient men daarna voldoende tijd in acht te nemen om het effect van de medicatie te laten uitdoven.
Literatuur
go back to reference Hirsh J. Mechanism of action and monitoring of anticoagulants. Sem Thromb Haemost 1985; 12: 1-11. Hirsh J. Mechanism of action and monitoring of anticoagulants. Sem Thromb Haemost 1985; 12: 1-11.
go back to reference Dick B, Jacobi FK. Kataraktchirurgie und Antikoagulation -derzeitiger Stand. Klin Monatsbl Augenheilkd 1996; 209: 340-46. Dick B, Jacobi FK. Kataraktchirurgie und Antikoagulation -derzeitiger Stand. Klin Monatsbl Augenheilkd 1996; 209: 340-46.
go back to reference Kammann J, Dornbach G, Linares I, Schuttrumpf R. Linsenimplantation bei Patienten unter Antikoagulantientherapie. Ophthalmologe 1994; 91: 486-89. Kammann J, Dornbach G, Linares I, Schuttrumpf R. Linsenimplantation bei Patienten unter Antikoagulantientherapie. Ophthalmologe 1994; 91: 486-89.
go back to reference Roudaut R, Lorient-Roudaut MF. Traitement antithrombotique chez le porteur de prothese valvulaire mecanique. Arch Mal Coeur Vaiss 1996; 89 (Suppl): 1543-50. Roudaut R, Lorient-Roudaut MF. Traitement antithrombotique chez le porteur de prothese valvulaire mecanique. Arch Mal Coeur Vaiss 1996; 89 (Suppl): 1543-50.
go back to reference Saour JN, Ali HA, Mammo LA, Sieck JO. Dental procedures in patients receiving oral anticoagulation therapy. J Heart Valve Dis 1994; 3: 315-17. Saour JN, Ali HA, Mammo LA, Sieck JO. Dental procedures in patients receiving oral anticoagulation therapy. J Heart Valve Dis 1994; 3: 315-17.
go back to reference Encke A. Chirurgie bei Patienten unter Anticoagulation bei Notfallund Elektiv Bedingungen. Chirurg 1997; 68: 670-74. Encke A. Chirurgie bei Patienten unter Anticoagulation bei Notfallund Elektiv Bedingungen. Chirurg 1997; 68: 670-74.
go back to reference International Committee on Thrombosis and Haemostasis and International Committee for Standardization in Hematology. Prothrombin time standardization: Report of the Expert Panel on oral anticoagulant control. Thromb Haemost 1979; 42: 1073-114. International Committee on Thrombosis and Haemostasis and International Committee for Standardization in Hematology. Prothrombin time standardization: Report of the Expert Panel on oral anticoagulant control. Thromb Haemost 1979; 42: 1073-114.
go back to reference Poller L. Progress in standardization in anticoagulant control. Hematol Rev 1987; 53: 155-56. Poller L. Progress in standardization in anticoagulant control. Hematol Rev 1987; 53: 155-56.
go back to reference Besselaar AM van den. International standardization of laboratory control of oral anticoagulant therapy: a survey of thromboplastin reagents used for prothrombin time testing. J Heart Valve Dis 1993; 2: 42-52. Besselaar AM van den. International standardization of laboratory control of oral anticoagulant therapy: a survey of thromboplastin reagents used for prothrombin time testing. J Heart Valve Dis 1993; 2: 42-52.
go back to reference Stevenson KJ, Craig S, Dufty JMK, Taberner DA. System ISI calibration: a universally applicable scheme is possible only when coumrin plasma calibrants are used. Br J Haematol 1997; 96: 435-41. Stevenson KJ, Craig S, Dufty JMK, Taberner DA. System ISI calibration: a universally applicable scheme is possible only when coumrin plasma calibrants are used. Br J Haematol 1997; 96: 435-41.
go back to reference Hirsh J, Levine M. Confusion over the therapeutic range of monitoring oral anticoagulant therapy in North America. Thromb Haemost 1988; 59: 129-32. Hirsh J, Levine M. Confusion over the therapeutic range of monitoring oral anticoagulant therapy in North America. Thromb Haemost 1988; 59: 129-32.
go back to reference Gurwitz JH, Goldberg RJ, Holden A, et al. Age-related risks of long-term oral anticoagulant therapy. Arch Intern Med 1988; 148: 1733-36. Gurwitz JH, Goldberg RJ, Holden A, et al. Age-related risks of long-term oral anticoagulant therapy. Arch Intern Med 1988; 148: 1733-36.
go back to reference Hirsh J, Poller L, Deykin D, Levine M, Dalen J. Optimal therapeutic range for oral anticoagulants. Chest 1989; 95 (suppl): 5-11. Hirsh J, Poller L, Deykin D, Levine M, Dalen J. Optimal therapeutic range for oral anticoagulants. Chest 1989; 95 (suppl): 5-11.
go back to reference Forfar JC. Prediction of hemorrhage during long-term oral coumarin anticoagulation by excessive prothrombin ratio. Am Heart J 1982; 103: 445-52. Forfar JC. Prediction of hemorrhage during long-term oral coumarin anticoagulation by excessive prothrombin ratio. Am Heart J 1982; 103: 445-52.
go back to reference Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a populationbased study in Rochester, Minnesota. Mayo Clin Proc 1995; 70: 725-33. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a populationbased study in Rochester, Minnesota. Mayo Clin Proc 1995; 70: 725-33.
go back to reference Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-52. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-52.
go back to reference Chesebro JH, Fuster V, Elveback LR. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983; 51: 1537-41. Chesebro JH, Fuster V, Elveback LR. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983; 51: 1537-41.
go back to reference Powers PJ, Gent M, Ray RM, et al. A randomized trial of less intensive post-operative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Int Med 1989; 149: 771-74. Powers PJ, Gent M, Ray RM, et al. A randomized trial of less intensive post-operative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Int Med 1989; 149: 771-74.
go back to reference Kadakia SC, Angueira CE, Ward JA, Moore M. Gastrointestinal endoscopy in patients taking antiplatelet agents and anticoagulants: survey of American Society for Gastrointestinal Endoscopy members. Gastrointest Endosc 1996; 44: 309-16. Kadakia SC, Angueira CE, Ward JA, Moore M. Gastrointestinal endoscopy in patients taking antiplatelet agents and anticoagulants: survey of American Society for Gastrointestinal Endoscopy members. Gastrointest Endosc 1996; 44: 309-16.
Metagegevens
Titel
Hoe is het beleid rondom staken en weer starten van antistollingsbehandeling?
Auteur
Prof.dr. C. Haanen
Copyright
2006
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-313-8808-0_1238